Shasqi

Executive Summary

Shasqi is a clinical-stage biotechnology company pioneering a novel tumor-targeting platform based on in-vivo click chemistry. Its proprietary CAPAC® platform separates the targeting moiety from the therapeutic payload, utilizing a bioorthogonal chemical reaction to activate drugs specifically at the tumor site. This approach aims to maximize drug concentration within tumors while minimizing systemic exposure and associated toxicities, potentially addressing key limitations of conventional chemotherapy and antibody-drug conjugates. Shasqi's technology holds promise for improving the therapeutic index of potent anticancer agents and expanding the repertoire of drugs that can be safely delivered systemically. The company has advanced its lead candidate into clinical development, with early studies evaluating safety, tolerability, and initial efficacy signals in solid tumors. While Shasqi remains in the relatively early stages of clinical validation, its differentiated platform has attracted interest from potential partners. Success in generating proof-of-concept data could validate the platform and unlock significant value. However, the company faces typical biotech risks including clinical trial execution, regulatory hurdles, and competition from other targeted delivery approaches.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1/2 safety and efficacy data readout50% success
• Q2 2026First patient dosed in Phase 2 expansion cohort80% success
• Q3 2026Strategic partnership or licensing deal for CAPAC platform30% success